Aligos Therapeutics, Inc. (ALGS)
| Market Cap | 38.55M |
| Revenue (ttm) | 2.19M |
| Net Income (ttm) | -24.19M |
| Shares Out | 6.19M |
| EPS (ttm) | -2.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,572 |
| Open | 6.49 |
| Previous Close | 6.43 |
| Day's Range | 6.22 - 6.58 |
| 52-Week Range | 4.20 - 13.69 |
| Beta | 2.62 |
| Analysts | Strong Buy |
| Price Target | 39.33 (+531.3%) |
| Earnings Date | May 5, 2026 |
About ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protea... [Read more]
Financial Performance
In 2025, Aligos Therapeutics's revenue was $2.19 million, a decrease of -44.59% compared to the previous year's $3.95 million. Losses were -$24.19 million, -81.56% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ALGS stock is "Strong Buy." The 12-month stock price target is $39.33, which is an increase of 531.30% from the latest price.
News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient o...
Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates
The agreement aims to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection in Greater China, which is expected to enhance its market position significantly.
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics ...
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) a clinical stage biopharmaceutical company focused on improving patient outcomes thro...
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through...
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-cl...
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i...
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i...
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists Oral presentation of ALG-055009 in vivo nonclinical data sho...
Aligos Therapeutics Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted a robust pipeline, with pevi showing unprecedented HBV DNA and antigen suppression, no resistance, and a strong safety profile. ALG-009 demonstrated superior efficacy in MASH and potential synergy with incretins. Key milestones are expected in 2024 and 2027.
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i...
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through ...
Aligos Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in...
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-cl...
Aligos Therapeutics Transcript: H.C. Wainwright Liver Disease Virtual Conference
The conference highlighted advances in HBV and MASH therapies, focusing on pevi's superior viral suppression, dual mechanisms, and regulatory progress. Pevi is positioned as a future standard for chronic suppression and as a backbone for functional cure regimens, while ALG-055009 shows promise for MASH and obesity.
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i...
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i...
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 Oral presentation will include the full 96-week and post-treatment fo...
Aligos Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
ALG-000184 shows unprecedented efficacy and safety in HBV, with no resistance and strong DNA/antigen suppression, positioning it as a new standard for chronic suppression and a backbone for cure regimens. ALG-055009 demonstrates promise in MASH, with key data and partnerships expected soon.
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-...
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i...
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in...
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes thro...
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through ...
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-cl...